Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
oh car car cartoon,your opinion means a great deal.Please continue with factless opines.Get in or get out,just my opinion.
Thanks Dr Dogs
Always good to read your posts.
Keep up the good work of informing us of the facts and your opinions on the company.
OUCH,Well I still feel lucky that I was able to get these at a great price.39
Will try to make monthly buys and see if 100,000 is attainable.Of course as that figure get closer I imagine the price will have increased a bit......starting today
On the bid for 8000 at.39,wish me luck just before it springs to .78
Thanks to Dr Dogs for the intelligent upbeat posts and for being a voice that keeps the board alive.
I am new to the board and am like minded about the potential for this company to become leading force in the CBD game.
Lots of interesting subjects on the site...enjoy http://www.stillcanna.com
Good one cat
Dr Dogs Is there a use for the mash after the CBD is removed.Is it possible to also isolate the THC and use that for something?
Hello Mr Berman
On AMAZON you should put the price per strip in the adverstisment.
I bet 50,000 shares that it would foster higher retail sales.
It's worth a shot, no?
That's some good reporting,glad you are keeping the board informed.
Just bought some more,I feel like we are onto a winner.
StillCanna Enters into a Strategic Relationship with CBD Logistics Expert for Secure Transportation of its Products Internationally
Stillcanna Logo (CNW Group/StillCanna Inc.)
News provided by
StillCanna Inc.
Jun 05, 2019, 03:01 ET
Share this article
VANCOUVER, June 5, 2019 /CNW/ - StillCanna Inc. (CSE:STIL, OTC:SCNNF, FRANKFURT:A2PEWA) ("STIL" or the "Company") is pleased to announce it has entered a strategic relationship with Sarah Yetman, an expert in the international transportation of industrial hemp and CBD.
Ms. Yetman has overseen the shipment of tens of thousands of kilograms of CBD into the USA and other countries. Ms. Yetman is also active in the supply of CBD products and biomass globally and will be representing StillCanna products to her existing customer base.
Ms. Yetman will be responsible for:
Arranging the shipment of biomass and CBD isolate and CBD distillate internationally;
Arranging all applicable insurance policies and required certificates of origin;
Organizing the clearance of shipments with the applicable Drug Enforcement Administration officials and customs officials;
Organizing the delivery of the CBD product to end customers once the CBD product has cleared customs; and
Organizing the product handling and testing at its final destination.
Ms. Yetman has been able to import products into the USA based sovereign ports of call and clear those products through customs using her existing relationships with both the Drug Enforcement Administration officials and US Customs officials.
"We are very impressed with the infrastructure that Sarah has been able to establish in both the USA and abroad," stated Jason Dussault, CEO of StillCanna. "Her expertise and experience provides an invaluable service to StillCanna and is an important link in our supply chain. This relationship allows our products to reach a wider international audience. Ms. Yetman also brings a broad international base of buyers for both CBD products and hemp biomass."
"I couldn't be more pleased to be working with StillCanna and providing them with the global logistics they require," said Sarah Yetman. "The contacts and infrastructure I have established is a custom fit for both the Company and myself. I look forward to implementing and overseeing the first of many shipments."
About StillCanna Inc.
StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe. The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company's market share in the European CBD industry.
On Behalf of the Board,
Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@StillCanna.com
Phone: 778-838-3692
Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the Company's intention to ship its first CBD products from Poland to the USA within the next few weeks and that the acquisition of Olimax is expected to result in an increase in the Company's market share of the European CBD industry. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that Company will be able to ship its first CBD products from Poland to the USA within the next few weeks and that the acquisition of Olimax will result in an increase in the Company's market share of the European CBD industry. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that that Company will not be able to ship its first CBD products from Poland to the USA within the next few weeks, or at all and that the acquisition of Olimax will not result in an increase in the Company's market share of the European CBD industry. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
SOURCE StillCanna Inc.
For further information: Joel Leonard, Chief Financial Officer and Director, E-mail: joel@StillCanna.com, Phone: 778-838-3692
Press Release
Europe's Booming CBD Market Grows Will Grow More Than 400%
Published: Aug 14, 2019 8:16 a.m. ET
Aug 14, 2019 (Financial News Media via COMTEX) -- FN Media Group Presents Potstocknews.com Market Commentary
New York, NY - August 14, 2019 – In February, the World Health Organization recommended that the United Nations remove pot and its key components from a list of highly-controlled substances under international drug treaties. Since then, there has been rapid development towards regulation and capitalization of pot-related industries, especially in Europe. Amidst reports that the CBD industry on the continent is exploding--with the Brightfield group projecting that in Europe the market will grow more 400% through 2023--there is remarkable room for growth in the CBD space. CBD cultivators and product manufacturers will have to move quickly to navigate existing regulation and produce nothing but the highest quality goods. By doing this, companies like StillCanna Inc. (STIL) SCNNF, +10.17%, GW Pharmaceuticals GWPH, +0.83%, The Green Organic Dutchman Holdings Ltd. (TGOD) (otcqx:TGODF), OrganiGram Holdings (OGI) OGI, +3.00%, and Tilray Inc. TLRY, -10.85% will establish in Europe a lucrative and trustworthy market for CBD products.
“CBD is just starting to take hold in Europe, with both product availability and consumer awareness still quite limited, Brightfield Managing Director, Bethany Gomez, recently highlighted. "This is a great opportunity for developed brands to enter and expand through Europe with far less competition than we’re seeing in the U.S."
Industry-Leading Cultivation and Extraction
StillCanna Inc. (STIL) (otcpk:SCNNF) has taken this opportunity to heart by combining its proprietary strengths with a number of key acquisitions and initiatives. In May, the company acquired legacy Polish hemp company Olimax, a vertically integrated licensed cultivator, extractor, and formulator of CBD. This purchase makes StillCanna by far the largest hemp cultivators in Poland and, when combined with its Romanian facilities, one of the largest in all of Europe.
Because hemp has been legal to grow in Poland for years, the company quickly got to work seeding more than 3,700 acres (1,500 hectares) of Polish farmland with its EU-certified, high-CBD-content hemp.
Of note, StillCanna is one of only three companies on the continent that has its own proprietary and registered hemp seed. Furthermore, its varietal strain has a gestation period of just 45 days, meaning that the company can plant two crops a year on a number of its properties to increase cultivation capacity starting in 2020.
But this cultivation capacity is only half the story. On August 7, StillCanna(STIL) SCNNF, +10.17% begun harvesting its crops through its patented method, which during the harvesting process maintains optimum CBD levels. This leads into a two-stage extraction plan for the hemp once it has been harvested
The first step involves the company's newest extraction facility in Poland called Nexus. Nexus has been optimized to produce over 1,230 kgs. of CBD isolate every month. StillCanna expects Nexus to be fully operational by Q4, allowing the company to begin fulfilling its delivery contracts.
The second step involves another CBD extraction facility, budgeted at an initial C$8.5 million to construct and equip with GMP certification which should be operational in 10 to 14 months. Named Horizon, this facility will be the technical culmination of knowledge gathered from the company's earlier facilities. Upon completion, it will be one of the most advanced, green, high-capacity facilities in the world, capable of producing more than 80 million grams of CBD per year.
By the end of this year, StillCanna will be able to produce up to 16 million grams of CBD, while next year it plans to double that number. By 2021 the company expects to be cultivating 12,500 acres and produce up to 60 million grams, with still plenty of room to grow beyond that.
Other Early Movers in the European CBD Market
Another company that is well-positioned to be a major provider of CBD products for Europe is GW Pharmaceuticals GWPH, +0.83%. The British-based company manufactures a CBD drug called Epidiolex which has already been prescribed to more than 12,000 patients. This has led GW Pharma to post net sales of $68.4 million during the last quarter and $101.9 million over the first half of 2019. The company has also seen positive results for its phase-three trial of the drug, which evaluated the effects of Epidiolex in patients with a rare and severe type of childhood epilepsy.
Meanwhile, The Green Organic Dutchman Holdings Ltd. (TGOD) (otcqx:TGODF), which recently filed an application to join the NASDAQ, has been extending its already impressive reach into new corners of the European CBD markets. At the start of the year, its JV partner, Knud Jepsen, received cannabis business authorization from the Danish Medicines Agency. Then, in May, TGOD entered the German CBD market through its subsidiary, HemPoland. The Dutchman's premium CBD brand will soon be lining the shelves of German pharmacies.
Already ahead of the curve, OrganiGram Holdings (OGI) OGI, +3.00% burst into the European market last year when it invested in Serbian-based hemp and CBD producer Eviana Health Corporation (EHC). Due to the fact that Eviana is licensed by the EU, it has easy access to Europe, and because it is a vertically integrated company, it can ensure its CBD maintains a high quality along with every phase of production.
Most recently, Tilray Inc. TLRY, -10.85% added nearly 50 acres of outdoor cultivation space to its holdings in Portugal, making for a total of just 60 indoor and outdoor acres in the country. Tilray will grow, harvest, and dry pot material for medicinal purposes at the site before transporting them to its manufacturing, processing and research space elsewhere in the country. The company plans to harvest its crop in the fall.
Europe-Focused Sales Offer Unique Prospects
In order to ensure that StillCanna(STIL) SCNNF, +10.17% capitalizes on its already prominent position in the CBD supply market, the company's founder Marc Crimeni relocated to Europe at the end of July to concentrate on bulk sales of CBD.
Noting that the European market for bulk CBD has been forecast to be "the largest in the world," Crimeni said that he is confident in his team members to handle management, agriculture, harvesting and extraction duties so that he can dedicate himself fully to sales.
This bodes well for StillCanna(STIL) SCNNF, +10.17%, as the company's London-based anchor-customer, Dragonfly BioSciences, already increased its minimum monthly order from 50 kgs. of CBD per month to over 170 kilos per month starting in July. This deal is expected to generate $46 million in revenue for the company over the next three years.
GW Pharmaceuticals GWPH, +0.83% is also already generating revenue from the new and exciting market, as it posted more than $100 million in net sales of its CBD drug Epidiolex in the first half of 2019. Likewise, The Green Organic Dutchman Holdings Ltd. (TGOD) (otcqx:TGODF) can expect increased revenue from Europe as its CBD products enter the Danish and German markets.
Canadian pot companies OrganiGram Holdings (OGI) OGI, +3.00% and Tilray Inc. TLRY, -10.85% are both poised to profit off the growing demand for CBD in Europe, though from opposite ends of the continent. The former invested in a hemp and CBD producer in Serbia, and the latter acquired almost 50 acres of medicinal pot cultivation space in Portugal.
As demand for CBD products in Europe continues to grow year over year, these are the companies expected to supply the continent. As they do, they will establish the industry standard for cost-effective production yielding high-quality goods.
For a free research report on StillCanna Inc. (STIL) SCNNF, +10.17%, visit www.potstocknews.com
Disclaimer: Potstocknews.com (PSN) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with PSN or any company mentioned herein. The commentary, views and opinions expressed in this release by PSN are solely those of PSN and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable PSN and FNM for any investment decisions by their readers or subscribers. PSN and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (PSN), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (PSN) has not independently verified or otherwise investigated all such information. None of the Author, PSN, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by PSN, a non-affiliated third party to distribute this release on behalf of StillCanna Inc.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PSN and FNM undertake no obligation to update such statements.
Media Contact:
FN Media Group, LLC
info@financialnewsmedia.com
+1(561)325-8757
Source: Potstocknews.com
The post Europe's Booming CBD Market Grows Will Grow More Than 400% appeared first on Financial News Media.
Quote
References
SCNNF
+0.05 +10.17%
GWPH
+1.27 +0.83%
OGI
+0.15 +3.00%
TLRY
-3.81 -10.85%
MarketWatch
Partner Center
Most Popular
This 31-year-old sold $700,000 of stuff online without buying any inventory
The trade war is already lost, Trump is doomed and this investment is about to go ‘ballistic,’ strategist says
Treasury is about to flood the market with debt to fund U.S.’s $1 trillion deficit — and that is a concern
She’s 63 and living by the beach in Mexico on $1,000 a month: ‘I can’t imagine living in the U.S. again’
Trump may want to buy Greenland, and the internet says, ‘Wait, what?’
PICK HIS LINENS
I am with dumass on this.Very similar history as to the time involved and the feeling that we are on the path to victory.
Hi Sushi fish,
I recognize your name from way back.Today I sold my 200 shares after 5 full years of cvm stuff. Will now wait till it hits 4 and try a buy back of some nice new shiny shares.This time I will be a relentless
trader making piles of dough.
Good luck fisherman and all holders,now that I am out it should go balistic.......r
Draggy
So good to see you are still kicking.Tell us again and again and again how we are making a big mistake being invested in this company.
I am selling today thanks for your advise.
Good one Jimmy Mc
Investor
Good to see you are keeping that novice chimp in line.Keep it up as the chimp seem to have much energy,not much brain power though.
Hey Kpisme
I'm with you on that R/S thing.I now have 2 hundred something shares with a cost of 24 dollars.
What else can you do but be patient,and I guess we are
Good day Zena and board people,
Just finished watching"What is Autophagy"
First I learned the proper pronunciation and second
the presentation was understandable to a lay person as myself.
Do not know how I missed it when Penny double first put it out,but i am more informed now......r
Thanks weedwarrior
Your comments and due diligence keep this board hopeful and informed.
Also thank you to the other contributors, but not the nay sayers and poo=poo crowd........r
What is the outlook for today's report?
I am waiting to buy some shares and would like your opinion
on if you think the stock will lose at the opening or continue to rise. TIA
Investor
I like your sense of humor,you keep the pigs penned with their own words.
Good one,Bio
GEORGIE
KEEP UP THE GOOD WORK YOU PROVIDE TO THIS BOARD!!!
YES I AM YELLING IT
you call yourself a checker,ha
Hey great green
Hold your ground against the flow of negative nellies.
I am sure that most of the peps that read here are on the side of the company,and your comments are a relief in the mist of the FUD.
What is that in miles??
My valley of tears is reading the nonsense from a very small battery
quote
Anyone have a good explanation why Anavex isn't at the JP Morgan Healthcare Conference?
GO TO THE BACK OF THE CLASS
Thanks Sokol,
For someone short on time you gave us an essay.
and THANKS TO ALL THE SMART GUYS AND GALS THAT CONTRIBUTE TO THIS BOARD.I wake up looking forward to reading the many comments,though understanding about 1/10 of the medical jargon.
Happy New Year 2 all
Swim towards the fin
RICLARK
Thanks for that info,it is a ray of light in an otherwise dismal board of messages.
Every so often the chips in our pile seem to dwindle,but we never are out of the game.
Let us keep our chins up and our eyes on the prize that we all believe we have.
The only thing to fear is self doubt.
Confusious or Churchill
Hey now,here we go almost a thousand shares traded before the bell.
First full week after the legal opening.I'm putting my entire social security check on this winner.
Keep the faith boys and girls,this baby is gonna get there exactly on time.Haste maketh waste,you don't get rich in 3 weeks.
We have alot of shares being traded,patience shall prevail or my name isn't Ruthaford B Hayes
Patience my friends,
This will happen,we have a perfect set up and some wise and hungry
people in charge.
At this price we are fortunate to be shareholders,in time this could turn into one of the best stock investments of our lives.
Patience,positivity, and more patience are free,so let us use them to our benefit.
With all the attendees,how much time will avxl have to present our findings?
Dado
Just wanted to also congradulate you and your wife on your recent blessing.
Will you take on a new name now??
Don't bograt that AVXL man